Drug
Ortataxel
Ortataxel is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed250%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
NCT00054314
completedphase_2
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
NCT01989884
unknownphase_2
BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
NCT00039169
unknownphase_2
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00039156
Clinical Trials (4)
Showing 4 of 4 trials
NCT00054314Phase 2
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
NCT01989884Phase 2
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
NCT00039169Phase 2
BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
NCT00039156Phase 2
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4